Charles River Laboratories CRL Gain/Loss on Asset Sales
Gain/Loss on Asset Sales at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnSaleOfBusiness.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's gain/loss on asset sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's gain/loss on asset sales?
- Charles River Laboratories (CRL) reported gain/loss on asset sales of -$117.98M in Q1 2026.
- How has Charles River Laboratories's gain/loss on asset sales changed year-over-year?
- Charles River Laboratories's gain/loss on asset sales decreased by 3594.7% year-over-year, from $3.38M to -$117.98M.
- What is the long-term trend for Charles River Laboratories's gain/loss on asset sales?
- Over 2 years (2021 to 2023), Charles River Laboratories's gain/loss on asset sales has grown at a -80.1% compound annual growth rate (CAGR), from $25.03M to -$995K.
- What does gain/loss on asset sales mean?
- The profit or loss realized from selling company assets or business segments.
- How do you interpret gain/loss on asset sales?
- Large gains indicate successful divestitures, while losses may suggest selling assets at a discount to raise liquidity.
- How does gain/loss on asset sales compare across companies?
- Depends on the company's M&A and restructuring strategy; common among large, diversified firms.